Other Events ·
Immutep reports A$48.5M cash, targets H2 CY27 trial start for efti in STS and HNSCC
IMMPIMMUTEP Ltd
Immutep Limited reported A$48.50 million in cash and term deposits as of September 30, 2026, with a runway extending into the first half of calendar year 2028. The company identified structural differences in its efti drug substance used in the discontinued TACTI-004 Phase III trial and contracted a new manufacturing run at the successful 200 L scale. Immutep intends to focus future registration-directed development of efti on head and neck squamous cell carcinoma (HNSCC) and neoadjuvant soft tissue sarcoma (STS), targeting study starts in H2 CY27. Additionally, its IMP761 program for autoimmune diseases is now a co-priority, with late-breaking data expected at the ACR Convergence in November 2026. The company also received an A$0.86 million rebate from Australia and €1.36 million from France under R&D tax incentive programs. Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases.